drugset / Trial / NCT00901069
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma. The investigators expect to enroll 12-24 patients in this trial over a 2 year accrual period.
Timeline
- Start
- 2009-05
- Primary completion
- 2012-01
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 25 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 50 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Azacitidine | Other / unclassified | 100 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Vincristine | Small molecule | — | — |